期刊文献+

盐酸氨溴索口腔崩解片溶出度测定方法的考察 被引量:1

Study on the dissolution of Ambroxol Hydrochloride Orally Disaggregation Tablets
下载PDF
导出
摘要 目的 建立以人工唾液为溶出介质,基于光纤传感系统原位测定盐酸氨溴索口腔崩解片溶出度的方法 .方法 用光纤药物溶出仪(FODT)选择5 mm间距探头,244 nm为检测波长,550 nm为参比波长,人工唾液900 mL为溶出介质,测定盐酸氨溴索口腔崩解片在不同溶出度测定条件下的溶出度和溶出曲线.结果采用桨法和转速为75 r·min^-1时,在6.6~39.6 mg·L^-1范围内具有较好的线性,加样回收率分别为100.6%,101.8%和100.5%;RSD分别为0.79%,0.44%和0.15%(n=3),日内精密度(RSD)分别为0.38%,0.44%和0.65%;日闻精密度(RSD)分别为0.64 %,0.59%和0.65%(n=5),盐酸氨溴索口腔崩解片在2 min之内溶出达90%以上.结论 该法操作简单,准确度高,重复性好,可用于该药的质量控制. Objective To establish a method in-situ monitoring the dissolution rate of Ambroxol Hydroehloride Orally Disaggregation Tablets by an artificial saliva solvent system base on a fiber-optical dissolution monitor(FODT). Methods Ambroxol Hydrochloride Orally Disaggregation Tablets were monitored by FODT with a 5 mm fiber optic probe. The dissolution conditions were: 900mL of artificial saliva, paddle at 50,75 or 100 r·min^-1 , measurement wavelength 244 nm, reference wavelength 550 nm, by using the measurement of dissolution rate dissolutive apparatus Ⅱ and apparatus I . Results Ambroxol hydrochloride with apparatus Ⅱ and 75 r ·min^-1 showed a well linearity with in the concentration at 6.6-39.6 mg· L^-1 , and the reggression coefficient of recovery were 100. 6% ,101.8% and 100. 5% ;the RSD were 0.79% ,0.44% and 0.15% ( n = 3). The RSD within-day were 0.38 %, 0. 44 % and 0. 65%, and the RSD day-to-day were 0. 64 %, 0.59 % and 0. 65%( n = 5), The dissolution rate of the Ambroxol Hydrochloride Oral Disaggregation Table was above 90 % within 2 min. Conclusion The method has the advantage of simpler operation, higher accuracy and well repetitiveness and could use in the quality control of this medicine.
出处 《西北药学杂志》 CAS 2010年第3期204-206,共3页 Northwest Pharmaceutical Journal
基金 "十一五"国家科技支撑计划重大项目(No:2006BAK03A16)
关键词 盐酸氨溴索口腔崩解片 溶出度 光纤药物溶出过程监测仪 ambroxol hydrochloride orally disaggregation tablets dissolution rate FODT ( fiber-optical pharmaceuties dissolution process monitor)
  • 相关文献

参考文献7

二级参考文献22

  • 1朱滨,邢君芬,陈坚.用光纤化学传感器连续在位监测甲硝唑片的体外溶出度[J].药学学报,1994,29(5):369-374. 被引量:18
  • 2贾伟元.氨溴索合成路线图解[J].中国医药工业杂志,1995,26(5):235-237. 被引量:18
  • 3胡雪莲,黄华,李英博.口腔崩解片的研究进展[J].中国医院药学杂志,2005,25(2):167-169. 被引量:27
  • 4FU YR,YANG SC,JEONG SH,et al.Orally fast disintegrating tablets:developments,technologies,taste-masking and clinical studies[J].Crit Rev Ther Drug Carrier Syst,2004,21 (6):433 -475.
  • 5SHIMIZU T,NAKANO Y,MORIMOTO S,et al.Formulation study for lansoprazole fast-disintegr-ating tablet.I.Effect of compression on dissolution behavior[J].Chem Pharm Bull,2003,51(8):942 -947.
  • 6ABDELBARY G,EOUANI C,PRINDERRE P.Determination of the in vitro disintegration profile of rapidly disintegrating tablets and correlation with oral disintegration[J].Int J Pharm,2005,292(1 -2):29 -41.
  • 7王洪泉 叶显撑 王娟 等.盐酸氨溴索片溶出度比较[J].中国药房,12:749-750.
  • 8陈坚,李伟,阎超,袁立懋,郭炬亮,周新继.基于多猝灭响应原理的PBA光纤化学膜传感器的性能和应用研究[J].中国科学(C辑),1997,27(1):69-75. 被引量:24
  • 9National Drug Specification,Vol 47(国家药品标准第47册).2004.
  • 10Ishai N, Bruce D J, Jonas J, et al. Application of fiber - optic dissolution testing for actual products. Pharm Technol,2001, May 01:33.

共引文献22

同被引文献11

  • 1Mori M, Takahashi S. Pharmacological and clinical properties of AIMIX(R) combination tablets LD g> HD, fixed-dose combination of irbesartan and amlodip- ine besilate[J]. Nihon Yakurigaku Zasshi, 2013, 142 (1) : 39-46.
  • 2Lambers Heerspink H J, Weldegiorgis M, Inker L A,et al. Estimated GFR decline as a surrogate end point for kidney failure a post hoe analysis from the reduc- tion of end points in non-insulin-dependent diabetes with the angiotensin II antagonist losartan (RENAAL) study and irbesartan diabetic nephropathy trial (IDNT) [J]. AmJ Kidney Dis, 2014,63(2): 244-250.
  • 3Zhu D, Gao P, Holtbruegge W, et al. A randomized, double-blind study to evaluate the efficacy and safety of a single-pill combination of telmisartan 80 mg/amlodip- ine 5 mg versus amlodipine 5 mg in hypertensive Asian patients[J]. J Int Med Res, 2014,42(1):52-65.
  • 4Bobrie G. I-combine study: assessment of efficacy and safety profile of irbesartan/amlodipine fixe&dose com- bination therapy compared with amlodipine monothera- py in hypertensive patients uncontrolled with amlodip- ine 5 mg monotherapy: a multicenter, phase UI, pro- spective, randomized, open-label with blinded-end point evaluation study[J]. Clin Ther, 2012, 34 (8) : 1705-1719.
  • 5Bobrie G. I-add study: assessment of efficacy and safe- ty profile of irbesartan/amlodipine fixed-dose combina- tion therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase , prospec- tive, randomized, open-label with blinded-end point e- valuation study[J]. Clin Ther, 2012, 34(8): 1720- 1734.
  • 6Costa P. An alternative method to the evaluation of similarity factor in dissolution testing [J]. Int J Pharm, 2001, 220(1): 77-83.
  • 7Berry M R, Likar M D. Statistical assessment of dis- solution and drug release profile similarity using a mod- el-dependent approach [J]. J Pharm Biomed Anal, 2007, 45(2): 194-200.
  • 8Shah V P,Tsong Y,Sathe P,et al. In vitro dissolution profile comparison-statistics and analysis of the similar- ity factor, f2[J]. PharmRes, 1998, 15(6): 889-896.
  • 9Duan J Z, Riviere K, Marroum P. In vivo bioequiva- lence and in vitro similarity factor (./'2) for dissolution profile comparisons of extended release formulations: how and when do they match[J]. Pharm Res, 2011, 28(5) : I144-1156.
  • 10孔爱英,谢沐风,郭长君,刘艳娥,靳守东.卡马西平片溶出度方法比较以及溶出曲线评价方法的探讨[J].中国药事,2011,25(2):162-165. 被引量:14

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部